Hey Jane LegitScript and Accreditation Status: Is It a Legitimate Telehealth Provider?

What Is Hey Jane and Who Is It For?

Hey Jane describes itself as a telehealth service built around reproductive autonomy. The platform primarily serves people who need medication abortion, ongoing contraception, emergency contraception, or STI screening and treatment. It operates on a cash-pay model with no insurance billing, which keeps pricing transparent but means you pay out of pocket unless you qualify for financial assistance.

The target user is a woman of reproductive age, typically between 18 and 45, who lives in a state where Hey Jane is licensed and who can safely receive care asynchronously. Because the core product is medication abortion, nearly every clinical decision on the platform intersects with reproductive-age physiology, gestational dating, and state law.

Who specifically benefits

• Women in states where in-clinic abortion access is limited or requires long travel
• Women who prefer privacy and do not want to appear at a physical clinic
• Women without health insurance or with insurance that excludes reproductive services
• Women seeking ongoing birth control or emergency contraception through a single platform

Who should look elsewhere

• Women outside Hey Jane's licensed states (the list changes as litigation evolves)
• Women with gestational age above 10 weeks last menstrual period (LMP), ectopic pregnancy risk, IUD in place, or clotting disorders. These are medical contraindications to the mifepristone-misoprostol regimen
• Women who want in-person follow-up as the primary care model

LegitScript Certification: Does Hey Jane Have It?

LegitScript is a third-party verification company that certifies telehealth platforms and online pharmacies as meeting standards for legal compliance, clinician licensing, prescription practices, and patient safety. LegitScript's healthcare merchant program is recognized by Google, Visa, Mastercard, and other platforms as a trust signal, which affects whether a site can run ads and accept card payments through major processors.

As of January 2025, Hey Jane does not appear in LegitScript's public directory of certified telehealth platforms. This is not unique to Hey Jane. Many smaller reproductive-health telehealth companies have not pursued LegitScript certification, partly because the certification process requires detailed documentation of prescribing protocols, pharmacy partnerships, and state-by-state licensing, and partly because LegitScript's own policy on abortion-related telehealth has been contested.

What the absence of LegitScript certification means in practice

The absence of LegitScript certification does not automatically mean a platform is unsafe or illegal. It means:

• The platform has not undergone (or has not passed) LegitScript's independent audit
• You cannot use LegitScript's public database to verify Hey Jane's compliance independently
• Payment processing and advertising relationships may be more complex for the company

What it does not mean

Lack of LegitScript certification does not mean Hey Jane's clinicians are unlicensed, that its pharmacy partners are unregulated, or that the medications it prescribes are counterfeit. Those factors depend on state medical board licensing and FDA regulatory oversight, not on LegitScript status alone.

FDA Oversight of the Medications Hey Jane Prescribes

The medications at the center of Hey Jane's service are mifepristone and misoprostol. The FDA approved mifepristone in 2000, and in January 2023 the FDA updated the mifepristone REMS (Risk Evaluation and Mitigation Strategy) to allow certified prescribers to prescribe it via telemedicine and send it through mail-order pharmacy, without requiring the patient to pick it up in person.

This regulatory change was significant. It created the legal framework under which platforms like Hey Jane operate. The prescriber must be REMS-certified, the dispensing pharmacy must be REMS-certified, and the patient must receive and sign a Patient Agreement Form before dispensing.

The FDA's 2023 REMS update specifically states that mifepristone may be dispensed by mail by certified pharmacies to patients whose prescriber has determined that the gestational age does not exceed 70 days (10 weeks LMP), that the pregnancy is intrauterine, and that the patient has no contraindications. This is the exact window and criteria Hey Jane uses for patient eligibility.

Mifepristone efficacy data

The two-drug regimen of mifepristone 200 mg orally followed 24 to 48 hours later by misoprostol 800 mcg buccally has a complete abortion rate of approximately 95 to 98 percent in pregnancies up to 70 days LMP, based on a pooled analysis of clinical trials. Serious complications including infection or hemorrhage requiring transfusion occur in fewer than 1 percent of cases in studies of over 200,000 medication abortions.

Sex-specific pharmacology of mifepristone

Mifepristone is a synthetic 19-norsteroid that competitively antagonizes progesterone receptors, which in pregnancy are responsible for maintaining decidual integrity and suppressing myometrial contractions. It has no meaningful activity in women who are not pregnant or not in the luteal phase. The drug's half-life is approximately 18 hours, and pharmacokinetic data show no clinically meaningful sex-based differences beyond what is already captured by the pregnancy-specific receptor state. Misoprostol, a prostaglandin E1 analog, causes cervical softening and uterine contractions. Its buccal absorption is consistent across reproductive-age women, with peak plasma concentration at approximately 30 minutes.

Pregnancy, Lactation, and Contraception: Required Safety Information

This section is required reading for any woman considering Hey Jane's services.

Pregnancy use (that is the point)

Mifepristone combined with misoprostol is indicated specifically for medical termination of intrauterine pregnancy through 70 days LMP. Both drugs are teratogenic if the pregnancy continues. The FDA prescribing information for mifepristone states that if the treatment fails to terminate the pregnancy, the patient must be counseled about the risks of continuing the pregnancy given the exposure to these agents. This is why confirming pregnancy location (ruling out ectopic) and gestational age before prescribing is non-negotiable.

Lactation

Mifepristone transfers into breast milk in small amounts. A pharmacokinetic study published in Contraception found that infant exposure through breast milk over 72 hours was estimated at 0.5 percent of the maternal weight-adjusted dose, which is generally considered below the threshold of clinical concern. Misoprostol and its active metabolite misoprostol acid are present in breast milk but degrade rapidly. The Academy of Breastfeeding Medicine and most reproductive health authorities consider a brief pumping-and-discarding period of 4 to 6 hours after misoprostol administration sufficient to minimize infant exposure, though formal ABM data on this specific regimen remain limited.

Postpartum women considering medication abortion for a subsequent pregnancy (which can occur as early as 3 weeks postpartum before return of menses) should discuss lactation timing with their clinician before scheduling.

Contraception after medication abortion

Ovulation can return as early as 8 days after a completed medication abortion. ACOG's guidance on contraception after pregnancy loss states that any contraceptive method may be initiated immediately following a completed abortion. Hey Jane offers ongoing contraception services, and clinicians on the platform can prescribe pills, patch, ring, or support IUD or implant referrals. If you do not want another pregnancy, contraception planning should happen at the same visit.

BBB Rating and Complaint History

The Better Business Bureau (BBB) is a nonprofit that collects consumer complaints and rates businesses on responsiveness and transparency, not on clinical quality. As of early 2025, Hey Jane is not BBB accredited, meaning it has not applied for or paid for BBB accreditation. Its BBB profile shows a small number of complaints, primarily in the categories of service delivery, communication delays, and billing.

To evaluate Hey Jane complaints critically, it helps to apply a structured framework:

Category 1: Service or delivery complaints. These are the most common type reported for reproductive telehealth platforms. Common issues include shipping delays (particularly relevant in states where medication must cross state lines), difficulty reaching a clinician for follow-up questions, and unexpected holds on prescription processing. These are real operational problems, but they differ fundamentally from safety complaints.

Category 2: Clinical outcome complaints. These are rare in the public BBB file for Hey Jane. When they appear, they typically involve patients who were found ineligible after completing the intake questionnaire and who felt the process was not clearly communicated. Eligibility screening protects patients; it is not a customer-service failure.

Category 3: Billing or refund complaints. Cash-pay telehealth platforms sometimes have disputes about refunds when a prescription cannot be completed due to ineligibility or state restrictions. These complaints do not reflect clinical quality.

A small complaint file relative to the volume of patients served is not a red flag on its own. Context matters. For comparison, the FDA's adverse event reporting system (FAERS) receives reports from healthcare providers and patients separately from consumer complaint databases like BBB; serious adverse events from mifepristone would appear there, not in the BBB file.

State Licensing and Legal Status

Hey Jane operates in states where telemedicine prescribing of mifepristone is legal. As of January 2025, medication abortion via telehealth is legally available in approximately 20 to 24 states plus the District of Columbia. Hey Jane's active state list is smaller than that ceiling because the company has made deliberate choices about which states to launch based on regulatory stability and operational capacity.

State medical boards license the individual physicians and nurse practitioners who prescribe through the platform. If you want to verify that a specific clinician is licensed in your state, you can search your state medical board's public database. Hey Jane does not publish individual prescriber license numbers on its website, which is common practice but means you need to request this information directly or verify it post-visit.

Interstate shield laws

Several states, including California, Colorado, Massachusetts, and New York, have enacted shield laws protecting clinicians who prescribe abortion medications to patients in states where abortion is restricted. ACOG has documented this patchwork of legal protections and notes that the legal field remains subject to ongoing litigation. Hey Jane operates within this framework; understanding which state's law governs your care depends on where the prescriber is licensed and where you receive the medication.

How Hey Jane Compares to Other Reproductive Telehealth Platforms

Several platforms offer similar medication abortion services, including Plan C-listed providers, Aid Access, and Choix. Each differs in LegitScript status, prescriber model, state availability, turnaround time, and cost structure.

• Aid Access operates with European-based prescribers and ships internationally, making it available in all 50 states but placing it outside standard FDA REMS compliance. It is designed for access in restricted states.
• Choix operates in a smaller number of states with licensed U.S. Prescribers and has pursued a more clinic-affiliated model.
• Hey Jane sits between these: U.S.-licensed prescribers, REMS-compliant pharmacy partnerships, but no LegitScript certification and a moderate state footprint.

Plan C's medication abortion provider guide evaluates these platforms on safety, legality, and access, and is a useful independent reference. Plan C is not on the WomanRx citation allow-list, so we note it here as a public resource without linking; you can search for it directly.

Who This Is Right For and Who Should Seek Another Option

Right for you if:

• You are pregnant, up to 10 weeks LMP, in a state where Hey Jane is licensed
• You prefer privacy, do not have reliable transportation to a clinic, or face logistical barriers to in-person care
• You want a cash-pay model with a transparent sliding-scale option
• You are comfortable with asynchronous communication and can manage a follow-up call or message rather than an in-person visit
• You are not breastfeeding a newborn without a plan for the 4 to 6 hour pumping interval

Not right for you if:

• You are outside Hey Jane's licensed states
• Your gestational age exceeds 70 days LMP (10 weeks)
• You have an IUD in place (must be removed before the regimen, or the regimen cannot proceed safely)
• You have a suspected ectopic pregnancy, uncontrolled coagulopathy, adrenal insufficiency, or are on long-term corticosteroids. These are listed contraindications in the mifepristone prescribing information
• You want a LegitScript-certified platform as a non-negotiable trust standard
• You are postmenopausal (not applicable by definition) or trying to conceive (medication abortion is incompatible with this goal)

What to Ask Before You Use Hey Jane

Before completing the intake questionnaire, have answers ready for these questions:

1. What is the first day of your last menstrual period? This determines gestational age.
2. Have you had any pregnancy confirmation, including ultrasound or serum beta-hCG? Ectopic pregnancy must be ruled out.
3. Do you have an IUD? It must be removed before starting the regimen.
4. Are you breastfeeding? If yes, plan the pumping schedule.
5. Do you take any blood thinners, corticosteroids, or medications that affect cytochrome P450 3A4? Mifepristone is metabolized by CYP3A4, and interactions with strong inducers (rifampin, carbamazepine) or inhibitors (ketoconazole, some HIV antiretrovirals) can affect its efficacy or tolerability.
6. What is your Rh blood type? Women who are Rh-negative may need Rh immunoglobulin (RhoGAM) within 72 hours of the procedure; this is a step Hey Jane's asynchronous model may or may not cover depending on your state, and you need a plan for it.

ACOG Practice Bulletin No. 225 on medication abortion provides the clinical standard of care against which any telehealth platform's protocol should be measured. You have the right to ask Hey Jane's clinician whether their protocol aligns with ACOG PB 225.

The Evidence Gap: What We Do Not Know About Telehealth Abortion Specifically in Women

Clinical trials of mifepristone-misoprostol have enrolled tens of thousands of women, but randomized controlled trial data specifically comparing telehealth-delivered vs. Clinic-delivered medication abortion are limited. A 2021 study in Obstetrics and Gynecology by Chong et al. Found comparable efficacy and safety between no-test telemedicine abortion and standard in-clinic care in a small prospective cohort, but the study was not powered as a non-inferiority trial. Larger implementation data from the UK's telemedicine abortion program during COVID-19 showed outcomes consistent with in-clinic care, but UK regulatory and pharmacy infrastructure differs from the U.S. Context.

What this means for you: the medication itself is well-studied. The delivery model via asynchronous telehealth is newer, and data on patient experience, follow-up completion rates, and rare adverse event detection in the telehealth context are still accumulating. Choosing a platform with clear follow-up protocols and an emergency contact pathway matters more than LegitScript status alone.